Personalized medicine, often known as precision medicine, is intended to differentiate tailored treatment from trial and error. The modern notion has grown to particularly integrate a patient's "omic profile" in disease prevention, diagnosis, and treatment. Precision medicine has shifted from an academic exercise to a clinical reality for some conditions, with others not far behind. Rapid genomic discoveries made possible by genome-wide association studies (GWAS) combined with decreasing sequencing and genotyping costs have shifted precision medicine from an academic exercise to a clinical reality for some conditions, while others are not far behind. With the advent of electronic health records (EHRs), it is now possible to conduct population-scale research while also successfully delivering individualized medication to individual patients via clinical decision support. The inclusion of historically under-represented groups in sufficient numbers to allow statistically accurate inferences of the influence of relevant risk variables, including genetic contributions to disease risk, is a major problem for precision medicine research. Precision medicine experts have acknowledged the need of increasing diversity and have used a range of methods to do so.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States